Ms. Jennifer Che, our President and Managing Director, spoke at the Hong Kong Intellectual Property Department’s IP Training Programme on patent commercialization and technology transfer. Since 2020, the IPD has partnered with the Vocational Training Council’s Institute of Professional Education and Knowledge to arrange various IP training programmes. Other speakers include Mr. Michael Lin – a strategic business consultant & President of IIPCC, Dr. David Ai from the London School of Economics and Political Science, and Dr. Vincent Zhong, an expert in IP licensing and technology transfer who worked at Netac Technology Co., Ltd.

Jennifer’s talk, titled ‘Building a Strategic Patent Portfolio for Commercialization,’ taught professionals how to strategically build patent portfolios with a business mindset. Aside from building IP, Jennifer also focused on topics such as IP licensing, ownership transfers, enforcement, and cross-border issues.

Attendees, including IP owners and executives from startups, SMEs, and large enterprises in the innovation sector, found her talk incredibly insightful and beneficial.

We are very thankful to the IPD and PEAK/VTC for this opportunity to help build a deeper understanding of IP and commercialization in Hong Kong.

我们的过去活动

Recommended Insights

China Releases Details on Patent Term Extension, Deferred Examination and More in the Latest Draft Implementation Rules of the New Chinese Patent Law

2020年12月11日
The China National Intellectual Property Administration (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

2023年1月4日
New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Top crossarrow-right